triazoles has been researched along with bms-663068 in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Henrich, TJ; Kuritzkes, DR | 1 |
| Hanna, GJ; Healy, MD; Hwang, C; Krystal, M; Lataillade, M; Ray, N; Whitcomb, J; Wind-Rotolo, M | 1 |
| Hanna, GJ; Krystal, M; Lataillade, M; Li, Z; Ray, N; Sun, Y; Zhou, N | 1 |
| Eggers, B; Fan, L; Fang, H; Hanna, GJ; Healy, M; Hwang, C; Krystal, M; Langley, DR; Lataillade, M; McAuliffe, B; Nowicka-Sans, B; Ray, N; Zhou, N | 1 |
| Bertz, R; Furlong, M; Hanna, GJ; Hruska, M; Hwang, C; Landry, IS; Shah, V; Zhu, L | 1 |
| Abu Tarif, M; Bertz, RJ; Boulton, DW; Hanna, GJ; Hruska, M; Joshi, S; Landry, I; Lataillade, M; Pitsiu, M; Sadler, BM; Zhu, L | 1 |
| Colonno, RJ; Gong, YF; Ho, HT; Kadow, JF; Langley, DR; Lin, PF; Matiskella, J; Meanwell, NA; Parker, DD; Pearce, BC; Ueda, Y; Wang, T; Yamanaka, GA; Yang, Z; Yin, Z; Zhang, Z; Zheng, M | 1 |
| Cocklin, S; Karadsheh, R; Meuser, ME | 1 |
| Arduino, RC; Bauch, T; Chen, M; Graviss, EA; Kimata, JT; Li, M; Liu, W; Wang, J | 1 |
1 review(s) available for triazoles and bms-663068
| Article | Year |
|---|---|
HIV-1 entry inhibitors: recent development and clinical use.
Topics: Antibodies, Monoclonal; Chemoprevention; Clinical Trials as Topic; Cyclohexanes; Disease Transmission, Infectious; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Maraviroc; Organophosphates; Piperazines; Triazoles; Virus Internalization | 2013 |
3 trial(s) available for triazoles and bms-663068
| Article | Year |
|---|---|
Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Disease Susceptibility; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Mutation, Missense; Organophosphates; Piperazines; Prodrugs; RNA, Viral; Treatment Outcome; Triazoles; Viral Load | 2013 |
Pharmacokinetic interactions between BMS-626529, the active moiety of the HIV-1 attachment inhibitor prodrug BMS-663068, and ritonavir or ritonavir-boosted atazanavir in healthy subjects.
Topics: Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV-1; Humans; Male; Middle Aged; Organophosphates; Piperazines; Ritonavir; Triazoles; Young Adult | 2015 |
Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Administration Schedule; Female; HIV Infections; Humans; Inhibitory Concentration 50; Male; Middle Aged; Organophosphates; Piperazines; Prodrugs; Triazoles | 2016 |
5 other study(ies) available for triazoles and bms-663068
| Article | Year |
|---|---|
Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
Topics: Anti-HIV Agents; Antibodies, Monoclonal; CCR5 Receptor Antagonists; CD4 Antigens; Cyclohexanes; Drug Resistance, Viral; Enfuvirtide; HEK293 Cells; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV-1; Humans; Maraviroc; Organophosphates; Peptide Fragments; Piperazines; Prodrugs; Receptors, CCR5; Receptors, CXCR4; Receptors, Virus; Triazoles; Virus Internalization | 2013 |
Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068.
Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Molecular Sequence Data; Organophosphates; Piperazines; Prodrugs; Reverse Genetics; Sequence Analysis, DNA; Triazoles | 2014 |
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
Topics: Animals; Anti-HIV Agents; Caco-2 Cells; Cell Membrane; Drug Discovery; HIV Envelope Protein gp120; HIV-1; Humans; Molecular Docking Simulation; Organophosphates; Permeability; Piperazines; Prodrugs; Protein Conformation; Rats; Triazoles; Virus Attachment | 2018 |
Composition and Orientation of the Core Region of Novel HIV-1 Entry Inhibitors Influences Metabolic Stability.
Topics: Anti-HIV Agents; Azabicyclo Compounds; Azetidines; Chromatography, Liquid; HEK293 Cells; HIV Core Protein p24; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Microsomes, Liver; Organophosphates; Piperazines; Protein Binding; Pyrrolidines; Tandem Mass Spectrometry; Triazoles | 2020 |
Clearance of HIV infection by selective elimination of host cells capable of producing HIV.
Topics: Animals; Antigens, CD34; Apoptosis; Autophagy; Azepines; CD4-Positive T-Lymphocytes; HIV Infections; HIV-1; Humans; Mice; Organophosphates; Piperazines; Pyridines; Pyrimidinones; RNA, Viral; T-Lymphocytes; Triazoles | 2020 |